A potential link between plasma short‑chain fatty acids, TNF‑α level and disease progression in non‑alcoholic fatty liver disease: A retrospective study

Xiong,Jing; Chen,Xia; Zhao,Zhijing; Liao,Ying; Zhou,Ting; Xiang,Qian

doi:10.3892/etm.2022.11536

A potential link between plasma short‑chain fatty acids, TNF‑α level and disease progression in non‑alcoholic fatty liver disease: A retrospective study

Authors:
- Jing Xiong
- Xia Chen
- Zhijing Zhao
- Ying Liao
- Ting Zhou
- Qian Xiang
View Affiliations

Affiliations: Department of Gastroenterology, The Sixth People's Hospital of Chengdu, Chengdu, Sichuan 610051, P.R. China
Published online on: July 28, 2022 https://doi.org/10.3892/etm.2022.11536
Article Number: 598
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The onset and progression of non‑alcoholic fatty liver disease (NAFLD) remains unclear, but short‑chain fatty acids (SCFAs) in circulation may participate in its pathogenesis by acting as inflammation inhibitors. The aim of this retrospective study was to investigate plasma concentrations of general SCFAs in healthy individuals and in patients with distinct stages of NAFLD. Three main SCFAs (including acetate, propionate and butyrate) were analyzed by gas chromatography. The plasma TNF‑α concentration was measured by ELISA. One‑way ANOVA, Spearman's correlation and Pearson's correlation analysis were performed to estimate the associations between SCFAs, TNF‑α and disease progression. Multiple linear stepwise regression was computed to explore the predictor variables of TNF‑α in circulation. A total of 71 patients with NAFLD [including 27 patients with NAFL, 20 patients with non‑alcoholic steatohepatitis (NASH) and 24 patients with NAFLD‑related cirrhosis (NAFLD‑cirrhosis)] and 9 healthy control (HC) subjects were enrolled for analysis. Although not statistically significant, plasma SCFAs were elevated in patients with NAFL compared with HC subjects, whereas the vast majority of SCFAs were statistically reduced in patients with NASH or NAFLD‑cirrhosis compared with patients with NAFL. Plasma SCFAs had no significant differences in NASH or NAFLD‑cirrhosis patients compared with HC subjects. In addition, significant negative correlations were observed between TNF‑α and SCFAs. The progression of NAFLD (β=0.849; P<0.001) and the decline of the total three SCFA concentrations (β=‑0.189; P<0.001) were recognized as independent risk variables related to the elevated peripheral TNF‑α in the multiple linear stepwise regression model. Plasma SCFA concentrations may alter with the development of NAFLD and may have a potential link to TNF‑α and the progression of NAFLD, which may serve a protective role toward disease advancement. Further mechanistic studies, such as analysis of gastrointestinal microecology, signaling pathways and functions involved in TNF‑α, need to be performed. Also, therapeutic supplementation of SCFAs for NASH and NAFLD‑cirrhosis needs further research and verification.

View Figures

View References

1	Eslam M, Sanyal AJ and George J: International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 158:1999–2014.e1. 2020.PubMed/NCBI View Article : Google Scholar
2	Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 73:202–209. 2020.PubMed/NCBI View Article : Google Scholar
3	Männistö VT, Salomaa V, Färkkilä M, Jula A, Männistö S, Erlund I, Sundvall J, Lundqvist A, Perola M and Åberg F: Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int. 41:2590–2600. 2021.PubMed/NCBI View Article : Google Scholar
4	Calzadilla Bertot L and Adams LA: The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 17(774)2016.PubMed/NCBI View Article : Google Scholar
5	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update. Zhonghua Gan Zang Bing Za Zhi. 26:195–203. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
6	Li B, Zhang C and Zhan YT: Nonalcoholic fatty liver disease cirrhosis: A review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol. 2018(2784537)2018.PubMed/NCBI View Article : Google Scholar
7	Cobbina E and Akhlaghi F: Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 49:197–211. 2017.PubMed/NCBI View Article : Google Scholar
8	Sangouni AA and Ghavamzadeh S: A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr. 13:2917–2922. 2019.PubMed/NCBI View Article : Google Scholar
9	Tarantino G, Citro V and Capone D: Nonalcoholic fatty liver disease: A challenge from mechanisms to therapy. J Clin Med. 9(15)2019.PubMed/NCBI View Article : Google Scholar
10	Safari Z and Gérard P: The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 76:1541–1558. 2019.PubMed/NCBI View Article : Google Scholar
11	Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI and Valdes AM: Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 11:569–580. 2020.PubMed/NCBI View Article : Google Scholar
12	Miura K and Ohnishi H: Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 20:7381–7391. 2014.PubMed/NCBI View Article : Google Scholar
13	Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A and Szabo G: Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 54:133–144. 2011.PubMed/NCBI View Article : Google Scholar
14	Silva YP, Bernardi A and Frozza RL: The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). 11(25)2020.PubMed/NCBI View Article : Google Scholar
15	Chan JC, Kioh DY, Yap GC, Lee BW and Chan EC: A novel LCMSMS method for quantitative measurement of short-chain fatty acids in human stool derivatized with ¹²C- and ¹³C-labelled aniline. J Pharm Biomed Anal. 138:43–53. 2017.PubMed/NCBI View Article : Google Scholar
16	Canfora EE, Meex RCR, Venema K and Blaak EE: Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 15:261–273. 2019.PubMed/NCBI View Article : Google Scholar
17	Koh A, De Vadder F, Kovatcheva-Datchary P and Bäckhed F: From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell. 165:1332–1345. 2016.PubMed/NCBI View Article : Google Scholar
18	Aragonès G, González-García S, Aguilar C, Richart C and Auguet T: Gut microbiota-derived mediators as potential markers in nonalcoholic fatty liver disease. Biomed Res Int. 2019(8507583)2019.PubMed/NCBI View Article : Google Scholar
19	Schilderink R, Verseijden C and de Jonge WJ: Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis. Front Immunol. 4(226)2013.PubMed/NCBI View Article : Google Scholar
20	Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L and Duvnjak M: Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 20:18070–18091. 2014.PubMed/NCBI View Article : Google Scholar
21	Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B and Reo NV: Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 91:1–9. 2015.PubMed/NCBI View Article : Google Scholar
22	Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P and Geier A: Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 6:1496–1507. 2018.PubMed/NCBI View Article : Google Scholar
23	Kundi ZM, Lee JC, Pihlajamäki J, Chan CB, Leung KS, So SSY, Nordlund E, Kolehmainen M and El-Nezami H: Dietary fiber from oat and rye brans ameliorate western diet-induced body weight gain and hepatic inflammation by the modulation of short-chain fatty acids, bile acids, and tryptophan metabolism. Mol Nutr Food Res. 65(e1900580)2021.PubMed/NCBI View Article : Google Scholar
24	Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, et al: Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31:1285–1297. 2011.PubMed/NCBI View Article : Google Scholar
25	He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, Zhao Y, Bai L, Hao X, Li X, et al: Short-Chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 21(6356)2020.PubMed/NCBI View Article : Google Scholar
26	den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud DJ and Bakker BM: Short-Chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-Dependent switch from lipogenesis to fat oxidation. Diabetes. 64:2398–2408. 2015.PubMed/NCBI View Article : Google Scholar
27	Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD and Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 115:1343–1351. 2005.PubMed/NCBI View Article : Google Scholar
28	Wolever TM, Brighenti F, Royall D, Jenkins AL and Jenkins DJ: Effect of rectal infusion of short chain fatty acids in human subjects. Am J Gastroenterol. 84:1027–1033. 1989.PubMed/NCBI
29	de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM and Escobar JS: Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 40:54–62. 2017.PubMed/NCBI View Article : Google Scholar
30	Juanola O, Ferrusquía-Acosta J, García-Villalba R, Zapater P, Magaz M, Marín A, Olivas P, Baiges A, Bellot P, Turon F, et al: Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J. 33:11595–11605. 2019.PubMed/NCBI View Article : Google Scholar
31	Aoki R, Onuki M, Hattori K, Ito M, Yamada T, Kamikado K, Kim YG, Nakamoto N, Kimura I, Clarke JM, et al: Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome. 9(188)2021.PubMed/NCBI View Article : Google Scholar
32	Tilg H, Adolph TE and Moschen AR: Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade. Hepatology. 73:833–842. 2021.PubMed/NCBI View Article : Google Scholar
33	Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, et al: NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 66:1037–1046. 2017.PubMed/NCBI View Article : Google Scholar
34	Alisi A, Carpino G, Oliveira FL, Panera N, Nobili V and Gaudio E: The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications. Mediators Inflamm. 2017(8162421)2017.PubMed/NCBI View Article : Google Scholar
35	Robinson SM and Mann DA: Role of nuclear factor kappa B in liver health and disease. Clin Sci (Lond). 118:691–705. 2010.PubMed/NCBI View Article : Google Scholar
36	Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, et al: Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 55:415–424. 2006.PubMed/NCBI View Article : Google Scholar
37	Alaaeddine N, Sidaoui J, Hilal G, Serhal R, Abedelrahman A and Khoury S: TNF-α messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. Eur Cytokine Netw. 23:107–111. 2012.PubMed/NCBI View Article : Google Scholar
38	Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, Park CY, Oh KW, Park SW and Lee WY: Tumor necrosis factor-α as a predictor for the development of nonalcoholic fatty liver disease: A 4-year follow-up study. Endocrinol Metab (Seoul). 28:41–45. 2013.PubMed/NCBI View Article : Google Scholar
39	Machado MG, Sencio V and Trottein F: Short-chain fatty acids as a potential treatment for infections: A closer look at the lungs. Infect Immun. 89(e0018821)2021.PubMed/NCBI View Article : Google Scholar
40	Wang S, Lv D, Jiang S, Jiang J, Liang M, Hou F and Chen Y: Quantitative reduction in short chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. Clin Sci (Lond). 133:1857–1870. 2019.PubMed/NCBI View Article : Google Scholar
41	Yang T, Yang H, Heng C, Wang H, Chen S, Hu Y, Jiang Z, Yu Q, Wang Z, Qian S, et al: Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. Food Funct. 11:10675–10689. 2020.PubMed/NCBI View Article : Google Scholar
42	Deng M, Qu F, Chen L, Liu C, Zhang M, Ren F, Guo H, Zhang H, Ge S, Wu C and Zhao L: SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD. J Endocrinol. 245:425–437. 2020.PubMed/NCBI View Article : Google Scholar
43	Liedtke C and Trautwein C: The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur J Cell Biol. 91:582–589. 2012.PubMed/NCBI View Article : Google Scholar
44	Li KZ, Liao ZY, Li YX, Ming ZY, Zhong JH, Wu GB, Huang S and Zhao YN: A20 rescues hepatocytes from apoptosis through the NF-κB signaling pathway in rats with acute liver failure. Biosci Rep. 39(BSR20180316)2019.PubMed/NCBI View Article : Google Scholar
45	García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T and Solís-Herruzo JA: Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology. 44:581–591. 2006.PubMed/NCBI View Article : Google Scholar